[ET Net News Agency, 9 September 2019] Citi Research lowered its target price for China
Resources Medical (01515) to HK$6.6 from HK$12.5 and downgraded its rating to "neutral"
from "buy".
The research house adjusted the sales trend on for-profit, sponsorship and IOT hospitals
and 2019-2021 EPS were changed by -17%,-21% and -24% respectively.
Citi is cautious on the existing hospitals' operation under government budgeting
control, and new hospital acquisitions remained slower than expected. It also cut down the
hospital revenue in its DCF model to reflect the slow M&A. (KL)